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Intrahepatic cholangiocarcinoma (ICC) is the second most common primary tumor of the liver. To
further define its clinicopathology and surgical management, we reviewed our experience. Clinical
presentations of 32 patients with ICC was similar to that with hepatocellular carcinoma. Jaundice
occurred in only 27 percent. ICC was unresectable due to advanced disease stage in 81 percent. Six
patients had curative resections with two 5 year disease free survivors. Underlying liver disease was
associated with ICC in 34 percent of patients.
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INTRODUCTION
Cholangiocarcinoma of the intrahepatic bile ducts-(peripheral cholangiocarcinoma)
is the second most common primary malignancy arising within the liver1. This
tumor, however, accounts for less than 10% of primary hepatic malignancies2’3.
Because of its relative rarity, little is known about either the clinicopathologic
features of this tumor or the results of therapy4’5. To further define the clinical
presentation and surgical management of this histologic subtype of primary hepatic
tumor, we reviewed the surgical management of patients with intrahepatic cholan-
giocarcinoma treated at our institution.
Patients and Methods
Thirty two patients with intrahepatic cholangiocarcinoma (ICC) were managed at
the Mayo Clinic between 1965 and 1980. Only those patients who had their initial
diagnosis and treatment at the Mayo Clinic were included in this review. ICC was
defined as a malignancy of intrahepatic bile duct origin presenting as a focal liver
mass. Patients with cholangiocarcinoma arising from the bile duct confluence,
extrahepatic bile duct, and the gallbladder, with or without local infiltration of the
liver, were excluded. A concurrent diagnosis of cirrhosis was based on the
histologic findings of diffuse bridging fibrosis and regenerative nodules regardless
of primary liver disease.
Patient demographics, clinical features, laboratory findings, operative manage-
ment, and hospital morbidity and mortality were recorded for all patients.
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Followup data were obtained for all patients by telephone interview, correspon-
dence, or review of the patients’ current medical records and extended from the
date of diagnosis to death or July 1989. All surviving patients have been followed
for a minimum of five years. Survival was determined by the Kaplan-Meier method
using the Statistical Analysis System (SAS) software package and was actual
because of the study period. No patient was lost to follow-up.
RESULTS
Demographics
There were 17 women and 15 men with a mean age of 55 years and a range of 31 to
81 years. Associated hepatobiliary and gastrointestinal diseases were not uncom-
mon (Table 1). Seven patients had cirrhosis and two additional patients had clinical
cirrhosis evident by the physical stigmata of chronic liver disease and varices,
though unconfirmed histologically. Two other patients had diffuse intrahepatic
primary sclerosing cholangitis, and five patients had inflammatory bowel disease.
One patient had past exposure to Thorotrast. Forty-six percent of patients had a
family history of carcinoma, though extrahepatic in origin. Sixteen patients had had
a prior cholecystectomy, 15 ofwhom had a cholecystectomy longer than six months
prior to the diagnosis of cholangiocarcinoma. Chronic exposure to tobacco was
present in 51% of patients: cigarettes in 34%, and cigar, pipe tobacco, or oral use in
17%. Five women had taken oral contraceptives. Alcohol abuse was documented
in 6%.
Signs and Symptoms
The clinical features of the patients are listed in Table 2. Abdominal pain or
discomfort, malaise, and weight loss were the primary presenting symptoms.
Hepatomegaly or an abdominal mass was the main physical finding. In contrast to
patients with extrahepatic cholangiocarcinoma, jaundice occurred in only 27% of
patients.
Table 1 Chronic hepatobiliary diseases in 32 patients with intrahepatic cholangiocarcinoma
Number of
Disease Patients %
Cirrhosis (biopsy proven) 7
Hemochromatosis 4
Secondary biliary 2
Unspecified
Sclerosing cholangitis 2
Inflammatory bowel disease 5
Chronic ulcerative colitis 3
Crohn’s disease
Nonspecific colitis
22
6
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Table 2 Clinical features of 32 patients with intrahepatic cholangiocarcinoma
Symptoms Frequency (%)
Pain 68
Fatigue 35
Weight loss 26
Anorexia 26
Pruritus 19
Fever 19
Jaundice 13
Nausea 11
Other gastrointestinal 19
(bloating, early satiety,
pressure)
Trhombophlebitis 3
Signs
Hepatomegaly 60
Nodular 33
Smooth 27
Mass 30
Jaundice 27
Ascites 17
Splenomegaly 10
Tender right upper quadrant 9
Stigmata chronic liver disease 9
Pathology and Extent of Disease
Histologically, 91% of patients had a pure cholangiocarcinoma and 9% had a
mixed cholangiohepatocellular carcinoma but with cholangiocarcinoma predomi-
nance. Ten percent of tumors were well-differentiated grade I, 50% were grade II,
and 40% grades III-IV. Tumors were solitary in 60% of patients and multicentric in
40%. Seventy-one percent of patients had bilobar hepatic involvement. The site of
origin of solitary cholangiocarcinomas or the dominant mass of multicentric
cholangiocarcinoma was distributed equally between the hepatic lobes. Of the 24
patients who had surgery exploration, four patients had documented regional nodal
metastases. Distant metastases to peritoneum, lung, and bone, respectively, were
documented in three patients.
Surgical Treatment
Eight patients (25%) had cholangiocarcinomas biopsied either percutaneously or at
peritoneoscopy. Bilobar multicentricity obviated exploration for resection.
Seventeen patients (53%) had exploratory celiotomy and biopsy only. Tumors in
these patients were judged unresectable because of major vascular invasion,
multicentricity, or extrahepatic lymph node metastases. Hepatic lobectomy in four
patients (12%) and wedge resection in two patients (6%) were performed with
curative intent. One patient underwent a palliative right hepatic lobectomy for a
symptomatic tumor with microscopic involvement at the margin of resection (Table
3).98 R.T. SCHLINKERT ET AL.
Table 3
Surgical Procedure Number %
None 8 25
Exploration with biopsy 17 53
Wedge resection for cure 2 6
Lobectomy for cure 4 13
Incomplete resection 3
Survival
Overall median survival was 5.1 months. The median survival for patients with
curative resection was 2.8 years (range 9.6 months to 7.4 years) with two patients
alive and disease free at 6.2 and 8.5 years (see Figure 1). The patient undergoing
palliative resection died from disease 3 years postoperatively. The median survival
of the 25 patients with unresectable tumors assessed intraoperatively was 3.6
months (range one week to 7.4 years). Interestingly, one 34-year-old woman had
spontaneous calcification of a multicentric tumor without evidence of distant tumor
progression and remains a long-term survivor in this group.
To determine whether survival was affected by factors other than resection, the
relationship of survival to tumor multicentricity, bilaterality, and histologic differ-
entiation was analysed. The median survival of solitary unilobar, unresected lesions
(N 4) of two months was not different than the median survival of three months
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for multicentric bilateral tumors (N= 10). The median survival of unresected
bilobar solitary tumors (N 8) was 12 months. Overall median survival for grade I,
II, and III tumors was 12, 8, and 8 months, respectively. Resected grade I, II, and
III tumors had a median survival of 4.9 years, 2.9 years, and 2 years, respectively,
whereas unresected lesions for the same categories were 12 months, 4 months, and
4 months, respectively. Palliative external beam irradiation in five patients and
adjunctive chemotherapy in 16 patients had no objective influence on survival
based on demonstrable disease progression after initiation of such therapy.
Morbidity
Of the 24 patients who underwent exploration, one postoperative death (4%)
occurred from advanced disease following biopsy alone. Four patients (16%) had
minor complications after exploration and biopsy" wound infection, lower extre-
mity deep vein thrombosis, transient biliary fistula, and prolonged ileus respecti-
vely. One major complication occurred following curative resection which con-
sisted of cholangitis from an obstructed T-tube which resolved with parenteral
antibiotics and T-tube irrigation.
DISCUSSION
This study demonstrates that intrahepatic cholangiocarcinoma presents clinically in
a similar fashion to primary hepatocellular carcinoma but in a distinctly different
manner than that of extrahepatic cholangiocarcinoma. The diagnosis is often
delayed until the disease has reached an advanced stage. Although a low rate of
resectability (18.7%) is the consequence of advanced disease stage, surgical
resection remains the only therapeutic modality which may afford prolonged
survival. The association with additional hepatobiliary pathology and inflammatory
bowel disease is noteworthy but whether significant etiologic relationships exist
remains unproven.
The presentation of intrahepatic cholangiocarcinoma is similar to that of other
intrahepatic malignancies2’3’4’5. Abdominal pain and fullness, anorexia, and malaise
are common findings. In contrast extrahepatic cholangiocarcinoma presents most
commonly with obstructive jaundice6’7’8. Jaundice in patients with intrahepatic
cholangiocarcinoma occurs at an advanced stage with extrinsic compression of the
hepatic duct confluence by tumor, diffuse liver replacement by tumor, or extrahe-
patic duct occlusion by tumor emboli. While most extrahepatic cholangiocarcino-
mas are solitary and localized, our study suggests that intrahepatic cholangiocarci-
nomas are frequently multicentric and diffuse. Clearly, this pathologic feature
makessurgical intervention for cure less likely and palliation difficult. Despite
extensive intrahepatic involvement, only 30% of our patients undergoing laparo-
tomy had proven metastatic disease. The propensity for both intra- and extrahepa-
tic cholangiocarcinoma to metastatize infrequently despite locally advanced prim-
ary disease represents a pathologic characteristic of this cell type7"8.
Worldwide, most patients with hepatocellular carcinomas have underlying cirr-
hosis. Although many chronic liver diseases have been well recognized as a
predisposing factor for carcinomas arising from hepatocytes, similar findings have
not been well documented for patients with intrahepatic cholangiocarcinoma.100 R.T. SCHLINKERT ET AL.
Clinical evidence strongly supports a relationship between cholangiocarcinoma of
either intra- or extrahepatic origin and sclerosing cholangitis. Ritchie et al. first
demonstrated an association between bile duct carcinoma and ulcerative colitis.
Subsequent studies have suggested that underlying sclerosing cholangitis, which is
frequently associated with ulcerative colitis, may predispose the bile duct epithe-
lium to malignant transformation 1’11. Recent reports 12’13 support the postulate that
the incidence of cholangiocarcinoma is increased in patients with sclerosing cholan-
gitis. Two patients had sclerosing cholangitis and five had inflammatory bowel
disease in this study. An association between intrahepatic cholangiocarcinoma and
cirrhosis is less firm. Edmonson and Steiner confirmed cirrhosis in 3 of 13 patients
(29%) with intrahepatic cholangiocarcinoma, but Kawarada et al. found no
evidence of cirrhosis in 11 patients. Our finding of cirrhosis in 23% of patients with
intrahepatic cholangiocarcinoma suggest a potential association.
Our patients with intrahepatic cholangiocarcinoma presented with advanced
disease and thus, our resectability rate was low. Long-term survival was poor
regardless of method of treatment, but survival after diagnosis was prolonged only
for those patients who underwent resection. Two patients are without evidence of
disease after 5 years. Chen et al. TM and Kawarada et al. have reported similar
median survival of 21 months and 18 months, respectively, after curative resection.
Although our study population was small, tumor grade was the only clinicopatholo-
gic factor associated with survival. In contrast to our findings and others,TM
Iwatsuki and Starz115 have not found long-term survival affected adversely by this
histologic subtype of primary hepatic malignancy. Despite the poor prognosis of
patients with intrahepatic cholangiocarcinoma, most surgeons concur that laepatc
resection offers the only chance for cure and at present should be pursued actively
and judiciously. Hepatic transplantation may have a role for multicentric tumors
unresectable by conventional hepatic resection. Indeed, given the high frequency in
intrahepatic multicentricity and the relatively low frequency of extrahepatic metas-
tases, hepatic transplantation is the most attractive alternative. To date, survival
after transplantation for malignancy remains poorx6. However it is difficult to
determine whether transplantation was performed for intrahepatic or extrahepatic
cholangiocarcinomas. Alternatively, Okamoto
17 has evaluated hepatic artery liga-
tion in patients with unresectable tumors and found that this modality offered a
slight but not significant improvement in survival in patients with primary hepatic
malignancies compared to those who underwent noncurative resections.
Summary
Intrahepatic cholangiocarcinoma presents insidiously and often late in its course.
Its presentation is closely different from that of extrahepatic cholangiocarcinoma
but quite similar to the presentation of intrahepatic hepatocellular carcinoma.
There appears to be an association with underlying hepatobiliary pathology and
while surgical cures are rare, resection appears to offer the only chance for cure in
these patients and should be pursued actively. Because of late diagnosis and
advanced disease at the time of presentation, our current energies should be
directed towards earlier diagnosis and perhaps the identification of effective
adjuvant chemo and/or radiotherapy following resection.INTRAHEPATIC CHOLANGIOCARCINOMA 101
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INVITED COMMENTARY
Worldwide, hepatocellular carcinoma (HCC) is by far the most common histologi-
cal type of primary liver cancer. In contrast, clinical experience with the cholangio-
cellular form is limited. Regarding surgical therapy and prognosis the extrahepatic
or hilar type must be clearly differentiated from the intrahepatic or peripheral
cholangiocarcinoma (CCC).102 R.T. SCHLINKERT ET AL.
In their review on clinical aspects, pathology, and treatment of cholangiocellular
carcinoma over a 15-year period Schlinkert et al. emphasize again that the general
prognosis of those patients is poor. The median survival of 25 patients with non-
resectable tumors was only 3.6 months. Due to advanced tumor stages the
resectability rate was very low (18.7%) but patients after curative resection showed
an improved median survival of 2.8 years, with 2 patients alive and disease free at
6.2 and 8.5 years, respectively. It is highly likely, that those prolonged survival
times are not only due to the possible earlier stage of resectable patients but mainly
due to surgical removal of the tumor. These both essential findings, that first the
resectability rate in CCC is extremely low and second that if anything, surgery plays
the main role in the therapeutic success are very much in accordance with our
observations.
The question whether local resectability can be extended by total hepatectomy
and subsequent liver transplantation in cases with advanced tumors has stimulated
many controversial discussions, but remains open. To date, we ourselves have
performed liver transplantation in 16 patients with intrahepatic cholangiocellular
carcinoma, including 3 with a mixed hepatocholangiocellular type of tumor. All
lesions were not resectable by conventional means; ;11 of 16 patients had advanced
tumor stages IV A or IV B according to the TNM classification. Despite the fact
that in half of the cases regional lymph nodes or distant metastases were not present
at the time of operation all patients surviving the procedure developed early tumor
recurrence, particularly within the liver, bone, and lungs. Median survival was only
3.7 months, our longest survivor died after 25 months. Presently, no patient
transplanted for cholangiocellular carcinoma is alive. With few exceptions similar
results have been reported by other authors.
From those disappointing results one must draw the conclusion that liver
transplantation alone can not be recommended for patients with cholangiocellular
carcinoma unless effective adjuvant therapy becomes available in the future.
Instead, all efforts should be directed towards identification of patients with an
early tumor stage who are amenable to radical surgery by partial liver resection.
In contrast, liver transplantation seems to offer some chance to patients with
extrahepatic cholangiocellular tumor, the Klatskin type. If there is irresectability
because of deep bilateral parenchymal infiltration or involvement of both hepatic
arterial branches but no lymph node involvement, we would propose liver trans-
plantation. Results are better than in intrahepatic cholangiocarcinoma in our series
and two patients are surviving now for more than 5 years free of recurrence.
Apparently there is a significant biological difference between intrahepatic and
extrahepatic cholangio-carcinomas.
P. Pichlmayr
B. Ringe
Hannover, FRG.